Stocks · News reference

HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

Aug 28, 2026, 10:07 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 28, 2026, 12:14 PMAvi Kapoor
Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.
Read original at benzinga
BBY DG ESTC GAP GENB
SEC EDGARAug 25, 2026, 11:28 PMSEC EDGAR
8-K filing — Generate Biomedicines, Inc. (GENB)
Filed: 2026-08-26 AccNo: 0001193125-26-365556 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
GENB
BenzingaAug 6, 2026, 2:16 PMBenzinga Newsdesk
Generate Biomedicines shares are trading lower after the company reported mixed Q2 financial results.
Read original at benzinga
GENB